Vol. 19/No. 18 | OncologyLive

Gene Signature Developed for High-Risk SCC

October 10, 2018

Gene expression-based biomarkers associated with disease recurrence in patients with cutaneous squamous cell carcinoma may help in identifying a population subset considered to have high-risk disease.

Persistence Paved the Path of Discovery for an Immunotherapy Pioneer

October 08, 2018

Thomas F. Gajewski, MD, PhD, has made inroads in the field of cancer immunotherapy, most notably discovering the connections between the microbiome and clinical outcomes—findings that will enable the creation of microbiota-modulating interventions to improve outcomes in patients undergoing cancer treatments.

A New Front Line Is Taking Shape in Metastatic Renal Cell Carcinoma

October 03, 2018

The dismal prognosis for patients with metastatic renal cell carcinoma has fueled an earnest quest for more effective treatments, culminating in a better understanding of the disease and regulatory approval of several new drugs and therapeutic combinations.

A Perfect Storm Brews for Biosimilar Marketing

October 03, 2018

Pressure to reduce costs associated with biologics is one of the forces driving the rapid expansion of biosimilars, which are biological drugs that are very similar to already approved reference biologics in terms of potency, safety, and efficacy.

ASCO Supports Expanded Adjuvant Therapy for Early Breast Cancer

October 02, 2018

Patients with early-stage breast cancer facing a high risk of recurrence would benefit from the expanded use of adjuvant therapy, according to updated guidelines from the American Society of Clinical Oncology.

Risk Prediction Calculators Multiply in Cancer Care

October 01, 2018

Like clinicians elsewhere, investigators from the University of Colorado, Denver, struggled not only to predict the likelihood that a particular patient would do well with surgery alone but also to convey their estimates in terms that patients would understand.